S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/20 - 3/24
Jet pitched wildly, killing 1, amid cockpit warnings: NTSB
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/20 - 3/24
Jet pitched wildly, killing 1, amid cockpit warnings: NTSB
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/20 - 3/24
Jet pitched wildly, killing 1, amid cockpit warnings: NTSB
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Closing prices for crude oil, gold and other commodities
Modern Day Options Trading For Beginners! (Ad)pixel
MarketBeat Week in Review – 3/20 - 3/24
Jet pitched wildly, killing 1, amid cockpit warnings: NTSB
Modern Day Options Trading For Beginners! (Ad)pixel
Germany, EU reach agreement in combustion engine row
Bank failures and rescue test Yellen's decades of experience
Biden To Unleash "Choke Point" Operation On America? (Ad)
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
NASDAQ:LPTX

Leap Therapeutics - LPTX Stock Forecast, Price & News

$0.32
-0.01 (-3.05%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.29
$0.34
50-Day Range
$0.32
$0.72
52-Week Range
$0.29
$1.95
Volume
1.20 million shs
Average Volume
553,981 shs
Market Capitalization
$31.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.80

Leap Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
780.8% Upside
$2.80 Price Target
Short Interest
Bearish
9.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of Leap Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

702nd out of 989 stocks

Pharmaceutical Preparations Industry

337th out of 480 stocks


LPTX stock logo

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

Mizuho Securities Remains a Buy on Leap Therapeutics (LPTX)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Robert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)
Leap Therapeutics (NASDAQ:LPTX) PT Lowered to $2.00 at Mizuho
Leap Therapeutics, Inc. (LPTX)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
LPTX Leap Therapeutics, Inc.
See More Headlines
Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Company Calendar

Last Earnings
3/24/2023
Today
3/25/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.80
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+780.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-40,590,000.00
Pretax Margin
-14,214.93%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$1.22 per share

Miscellaneous

Free Float
86,643,000
Market Cap
$31.48 million
Optionable
Not Optionable
Beta
0.75

Key Executives

  • Doug E. Onsi
    President, CEO, CFO, Secretary & Treasurer
  • Augustine J. Lawlor
    Chief Operating Officer
  • Cynthia Sirard
    Chief Medical Officer
  • Michael Haas
    Head-Research
  • Jason S. Baum
    Vice President & Head-Translational Medicine













LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1-year target prices for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 780.8% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2023?

Leap Therapeutics' stock was trading at $0.45 at the beginning of the year. Since then, LPTX stock has decreased by 29.4% and is now trading at $0.3179.
View the best growth stocks for 2023 here
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Friday, March, 24th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02.

What other stocks do shareholders of Leap Therapeutics own?
What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include 683 Capital Management LLC (2.78%), Key Client Fiduciary Advisors LLC (1.36%), Element Capital Management LLC (1.17%), Millennium Management LLC (1.12%), Renaissance Technologies LLC (0.93%) and Knott David M Jr (0.85%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $0.32.

How much money does Leap Therapeutics make?

Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $31.48 million and generates $1.50 million in revenue each year. The company earns $-40,590,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 3/25/2023 by MarketBeat.com Staff